Overview

Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

Status:
Terminated

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.

Phase:

Phase 1

Details

Lead Sponsor:

Fovea Pharmaceuticals SA

Treatments:

Ecallantide